Jeito Capital is building a strong and diversified portfolio in Biopharma and innovative medical companies.
Neogene TherapeuticsOncology - Cell Therapy
Acquired by AstraZeneca
Finalised in January 2023
Round of $110 million
Sparing VisionOphtalmology - Gene Therapy
€44,5 million - September 2020
€75 million - Septembre 2022
innoSkelRare bone Diseases - Gene Therapy
Round of €20 million
PulmocideInhaled Respiratory Medicine
$92 million - May 2021
$52 million - December 2022
Alentis TherapeuticsFibrotic Diseases Medicine
CHF60 million - June 2021
€96 million - April 2023
Quell TherapeuticsT-reg cell therapy in auto-immune and inflammatory diseases
Round of $156 million
NMD PharmaSevere neuromuscular diseases
Round of €35 million
EyeBioEye disease therapies
Round of $65 million
Round of €80 million
Round of $76 million
HI-BioAuto-Immune Diseases - Antibody
Round of $120 million
Round of €50 million
Noema PharmaDEBILITATING CENTRAL NERVOUS SYSTEM DISORDERS
Round of €104 million
Corteria PharmaceuticalsCARDIOVASCULAR DISEASES
Round of €65 million
Oncology – Cell therapy
Round of $110 million – September 2020 and Acquisition by AstraZeneca for $320 million – January 2023
Negoene Therapeutics is a preclinical biotechnology company at the forefront of developing next-generation, fully personalized T-cell therapies targeting a wide range of cancers.
On 29 November 2022, AstraZeneca announced its acquisition of Neogene, which was finalised on the 16th of January 2023, for a total consideration of up to $320 million. Through this transaction, AstraZeneca strengthens its cell therapy portfolio that aims to empower and equip the immune system’s T cells, to more effectively fight cancer.
Ophtalmology – Gene Therapy
Rounds of €44,5 million – September 2020 and €75 million – September 2022
SparingVision is specialized in the research and development of ophthalmic treatments, particularly in the field of hereditary retinal degeneration.
Rare bone diseases – Gene therapy
Round of €20 million – December 2020
Innoskel is a French biotechnology company focused on the development of genetic therapies for rare skeletal diseases that can cause dwarfism and severe deformities.
Inhaled respiratory medicine
Rounds of $92 million – May 2021 and $52 million – December 2022
Pulmocide is a UK-based biotechnology company developing a leading range of first-in-class inhaled anti-infectives for the targeted treatment of life-threatening lung infections.
Fibrotic diseases medicine
Round of CHF60 million – June 2021
Alentis Therapeutics is a Swiss-based biotechnology company with R&D activities in France that focuses on the development of highly innovative treatments for fibrotic diseases using monoclonal antibodies targeting Claudin-1.
T-reg cell therapy in auto-immune and inflammatory diseases
Round of $156 million – November 2021
Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.
Severe neuromuscular diseases
Round of €35 million – February 2022
NMD Pharma A/S, is a private biotechnology company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity.
Round of $65 million – February 2022
EyeBio is a newly launched global company developing the next generation of eye disease therapies
Founded by two pioneers in ophthalmology drug development to build and advance diversified pipeline of ocular therapies
Jeito selects EyeBio as its 8th investment and continues to build a strong & diversified portfolio of companies with groundbreaking therapies in areas of high unmet need
Round of €80 million – March 2022
Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.
The financing will allow Precirix to advance its pipeline of precision radiopharmaceuticals.
Round of $76 million – April 2022
CDR-Life is a Swiss biotechnology company at the forefront of a new class of highly tumor-specific immuno-oncology therapeutics.
CDR-Life leverages the unique expertise and track record of its founders, who together have developed new approved drugs and entered into major biotechnology agreements.
Jeito chooses CDR-Life as its 10th investment and continues to build a strong and diversified portfolio of companies with breakthrough therapies in areas of unmet needs.
Auto-Immune Diseases – Antibody
Round of $120 million – November 2022
Human Immunology Biosciences (HI-Bio) is a San Francisco-based Phase II clinical-stage Biopharma company, with European development activities.
HI-Bio develops targeted therapies for patients suffering from severe immune-mediated diseases (IMD). It has several late-stage clinical programmes and a strong translational platform, enabling it to address many diseases with unmet medical needs.
Round of €50 million – November 2022
CatalYm is a Phase II clinical-stage Biopharma company developing novel immunotherapies to fight cancer. It is based in Munich.
Its lead drug candidate, Visugromab, is a monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), an inhibitor of immune cell infiltration into the tumor tissue.
DEBILITATING CENTRAL NERVOUS SYSTEM DISORDERS
Round of €104 million – March 2023
Noema Pharma is a clinical-stage biotechnology company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks.
The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche.
Round of €65 million – September 2023
Corteria Pharmaceuticals is a late preclinical stage biopharma company, developing first-in-class therapies with promising novel approaches for unaddressed heart failure subpopulations, addressing high unmet medical needs. It is based in France.
The company’s pipeline includes three therapies – including two programmes in-licensed from Sanofi – aimed at treating worsening heart failure, right heart failure and acute heart failure with hyponatremia. The Biopharma has the potential for wider exploitation in chronic cardiometabolic diseases.
At a glance